Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Buys Clinical Data And Extends Its Antidepressant Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

The Lexapro maker will pay $1.2 billion upfront plus potential milestones to gain a recently approved antidepressant Viibryd.

You may also be interested in...



Blend Hopes To Improve Upon Performance Of Antibody-Drug Conjugates

While its most advanced program is a prodrug of cisplatin designed to enter tumors as they absorb albumin, Blend is particularly excited about Pentarins, its novel class of conjugated cancer therapeutics.

Brintellix Label Gives Lundbeck Ground For Tolerability Claims

Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.

Will Saunders Bring Transformation To Forest?

The specialty pharma long has been scrutinized for its decisions regarding the patent cliff and business development. Now, a new CEO will have the chance to keep the company on its current course or mirror the transformations he’s put in motion at other companies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel